ONYDA XR (clonidine HCl) prior authorization criteria
Customize your policy alerts
Sign up for all Mississippi Division of Medicaid policy alerts
Know when Mississippi Division of Medicaid releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization requirements and coverage criteria for ONYDA XR (clonidine hydrochloride) for treatment of ADHD in pediatric patients, including initial and re-authorization conditions and dosing limits.
No material clinical or coverage changes in this revision.
Coverage Criteria for ONYDA XR (clonidine HCl)
Initial Authorization
Covered when ALL of the following are met:
Initial authorization duration: 1 year
Re-Authorization
Covered when ALL of the following are met:
Re-authorization duration: 1 year
Any request will be excluded when the prescribed dose exceeds 0.4 mg (4 mL) per day or when required documentation and criteria are not provided. Specifically, requests lacking evidence that the patient meets the minimum age per the package insert, lacks an ADHD diagnosis, does not include the prescriber’s clinical rationale for not using stimulants, or fails to document inadequate response/contraindication/intolerance to all preferred non-stimulants may be denied.
Use of ONYDA XR beyond the maximum daily dose of 0.4 mg (4 mL) per day is not supported by the coverage criteria. Requests for treatment at doses above this threshold must include compelling clinical justification and will be evaluated against the policy criteria; absent that justification, coverage is not authorized. Similarly, initiation or continuation of therapy without documented trials (or documented contraindication/intolerance) of all preferred non-stimulant alternatives, or without a prescriber’s documented rationale for why stimulants cannot be used, does not meet the criteria for coverage and may result in denial.
Dose Limits and Coding Summary
Provider Actions, Documentation, and Denial Triggers
Prior authorization required; approvals are 1 year
Prior authorization is required for ONYDA XR (clonidine HCl). When criteria are met, initial and re-authorization approvals are each granted for 1 year.
Step therapy — trial/failure of preferred non‑stimulants required
Patient must have documented inadequate response, contraindication, or intolerance to all preferred non-stimulants, and the prescriber must document why stimulants cannot be utilized before ONYDA XR will be approved.
Required documentation to include with PA
Submit the Universal PA Form and supporting clinical documentation with the prior authorization request.
- Documentation of ADHD diagnosis
- Prescriber's clinical rationale why stimulants cannot be utilized
- Documentation of inadequate response, contraindication, or intolerance to all preferred non-stimulants
- Prescribed dose and dosing information showing ≤ 0.4 mg (4 mL) per day
Common triggers for denial
Requests may be denied if the patient does not meet age requirements, lacks an ADHD diagnosis, has no documented rationale for not using stimulants, has not failed preferred non-stimulants, or if the prescribed dose exceeds the 0.4 mg/day limit.
- Patient below the minimum age per package insert
- No diagnosis of ADHD documented
- No prescriber rationale explaining why stimulants cannot be utilized
- No documentation of inadequate response/contraindication/intolerance to all preferred non-stimulants
- Prescribed dose exceeds 0.4 mg (4 mL) per day
- Lack of positive clinical response at re-authorization
Medication Details and Definitions
Medication Treatment Modality
Medication (ONDYA XR/clonidine HCl)
Formulation and dosing per product information
Background
ONYDA XR is an extended‑release oral suspension formulation of clonidine hydrochloride indicated for treatment of attention‑deficit/hyperactivity disorder in pediatric patients aged ≥6 years. It is a centrally acting alpha2‑adrenergic agonist used as monotherapy or as adjunctive therapy to central nervous system stimulants. The recommended initiation is 0.1 mg at bedtime with weekly titration by 0.1 mg increments to a maximum of 0.4 mg daily.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.